Prolonged schedule of temozolomide (Temodal) plus liposmal doxorubicin (Caelyx) in advanced solid cancers

Temozolomide (Temodal) is an oral imidazotetrazine. Increased temozolomide exposure and subsequent depletion of O-6-alkylguanine alkyltransferase may improve the activity of temozolomide. The rationale for investigating temozolomide plus Caelyx is based on their antitumor activity, their formulation and no significant overlapping toxicities. We conducted a study of a prolonged schedule of temozolomide (orally on days 1-7 and 15-21) plus Caelyx (day 1) every 28 days. Twenty-one patients (melanoma n = 10, sarcoma n = 7 and other n = 4) were assigned to four dose levels (DL; temozolomide + Caelyx, mg/m(2)): DL1: 100 + 30 (n = 3 patients), DL2: 100 + 40 (n = 6 patients), DL3: 125 + 40 (n = 6 patients) and DL4: 150 + 40 (n = 6 patients). Dose-limiting toxicities were noted after 2 or more cycles in one patient at DL3 (stomatitis) and one patient at DL4 (grade 4 ANC greater than or equal to 7 days). Treatment delays and/or dose reductions (due to hematological toxicity) were necessary in five of six patients receiving DL4 compared with one of six patients at DL3, and one patient at DL1 and 2. Thus, the recommended dose was temozolomide 125 mg/m(2) (daily for 7 days every other week) plus Caelyx 40 mg/m(2) (day 1 every 4 weeks). Other toxicities were mild. Antitumor activity was observed in eight patients, including one complete response (melanoma), three partial responses (one melanoma, two sarcomas) and four patients with stable disease (three melanomas, one Ewing), with a duration lasting from 14 to 135 + weeks. Two melanoma patients showed tumor stabilization in non-irradiated cerebral lesions. This schedule of temozolomide allowed higher dose intensity (1750 mg/m(2) in 4 weeks) compared to the standard 5-day regimen (1000 mg/m(2) in the same amount of time). (C) 2004 Lippincott Williams Wilkins.